Presentation is loading. Please wait.

Presentation is loading. Please wait.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Published byAhmet Marušič Modified over 6 years ago

Similar presentations

Presentation on theme: "Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R"— Presentation transcript:

1 Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma 
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R. Bergey, MSc, MPH, Seema S. Sonnad, PhD, John C. Kucharczuk, MD, Arthur Staddon, MD, Larry R. Kaiser, MD, Joseph B. Shrager, MD  Journal of Thoracic Oncology  Volume 6, Issue 5, Pages (May 2011) DOI: /JTO.0b013e f5c Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier curve of overall survival after pulmonary metastasectomy for soft tissue sarcoma. Three-year survival and 5-year survival were 67% and 52%, respectively. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e f5c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier curve of disease-free survival after pulmonary metastasectomy for soft tissue sarcoma. Three-year and 5-year survivals were 17% and 10%, respectively. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e f5c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier curve of overall survival after pulmonary metastasectomy for soft tissue sarcoma with adjuvant chemotherapy versus no chemotherapy (p = 0.82). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e f5c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Kaplan-Meier curve of disease-free survival after pulmonary metastasectomy for soft tissue sarcoma with adjuvant chemotherapy versus no chemotherapy (p = 0.88). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e f5c) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R"

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.

Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study  Thomas.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Similar presentations

Ads by Google